What changed in this filing

/stocks — the workspaceLOADING

Item 7. Management’s Discussion and Analysis

2025-02-13 compared with 2024-02-16 · 201 added, 172 removed, 469 unchanged (44% of the section changed)

6 unchanged sentences

Innovative Medicine and MedTech.

The Innovative Medicine segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases.

The Innovative Medicine segment is focused on the following therapeutic areas:

Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolism.

Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions and Vision fields.

The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Cardiovascular (previously referred to as Interventional Solutions) and Vision fields.

These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company.

This Committee oversees and coordinates the activities of the Innovative Medicine and MedTech business segments.

The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer).The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels.

Within the strategic parameters provided by the Executive Committee, senior management groups at U.S.

and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.

In all of its product lines, the Company competes with other companies both locally and globally, throughout the world.

4 unchanged sentences

Management’s objectives

With “Our Credo” as the foundation, the Company’s purpose is to blend heart, science and ingenuity to profoundly impact health for humanity.

The Company, believes health is everything.

With Our Credo as the foundation, the Company believes health is everything.

The Company's strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal.

2 unchanged sentences

In 2024, $17.2 billion was invested in research and development reflecting management’s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly impact of health for humanity.

A critical driver of the Company’s success is the diversity of its 131,900 employees worldwide.

Our approximately 138,100 employees are critical drivers of the Company’s success.

Employees are empowered and inspired to lead with Our Credo and purpose as guides.

4 unchanged sentences

(net of cash acquired)

*Includes acquisitions of in process research and development assets that were not accounted for as a business combination

Dividends paid

* Includes business combinations and asset acquisitions

Results of operations

Analysis of consolidated sales

For discussion on results of operations and financial condition pertaining to the fiscal years 2022 and 2021 see the Company’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, Item 7.

For discussion on results of operations and financial condition pertaining to the fiscal years 2023 and 2022 see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, Item 7.

Management's discussion and analysis of results of operations and financial condition.

7 unchanged sentences

Total 4.3 % 6.5 %

The net impact of acquisitions and divestitures on the worldwide sales growth was a positive impact of 1.5% in 2023 and no impact in 2022.

The net impact of acquisitions and divestitures on the worldwide sales growth was a positive impact of 0.5% in 2024 and a positive impact of 1.5% in 2023.

Sales by U.S.

1 unchanged sentence

This represents increases of 8.3% in 2024 and 10.6% in 2023.

In the fiscal 2024, acquisitions and divestitures had a net positive impact of 0.7% on the U.S.

operational sales growth.

Sales by international companies were $38.5 billion in 2024 and $38.7 billion in 2023.

This represents an increase of 1.9% in 2023 and a decrease of 0.2% in 2022.

This represents a decrease of 0.5% in 2024 and an increase of 1.9% in 2023.

In fiscal 2024, acquisitions and divestitures had a net positive impact of 0.2% on the international operational sales growth.

In fiscal 2024, the impact of the Covid-19 Vaccine sales decline on the international operational sales was a negative 2.6%.

The five-year compound annual growth rates for worldwide, U.S.

2 unchanged sentences

and international sales were 4.0%, 5.4% and 2.5%, respectively.

In 2023, sales by companies in Europe experienced a decline of 1.2% as compared to the prior year, which included an operational decline of 2.2% and a positive currency impact of 1.0%.

In fiscal 2023, the net impact of the Covid-19 Vaccine and the loss of exclusivity of Zytiga on the European regions change in operational sales was a negative 9.8%.

Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 10.7% as compared to the prior year, which included operational growth of 15.8%, and a negative currency impact of 5.1%.

Sales by companies in the Asia-Pacific, Africa region achieved growth of 3.9% as compared to the prior year, including operational growth of 9.5% and a negative currency impact of 5.6%.

2024 Annual Report

In 2023, the Company utilized three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total consolidated revenues.

In 2022, the Company had three wholesalers distributing products for both segments that represented approximately 18.9%, 15.0% and 13.8% of the total consolidated revenues.

In 2024, sales by companies in Europe experienced a decline of 1.0% as compared to the prior year, which included an operational decline of 0.6% and a negative currency impact of 0.4%.

In fiscal 2024, the net impact of the Covid-19 Vaccine on the European regions change in operational sales was a negative 4.7%.

Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 3.6% as compared to the prior year, which included operational growth of 20.4%, and a negative currency impact of 16.8%.

Sales by companies in the Asia-Pacific, Africa region experienced a decline of 1.2% as compared to the prior year, including operational growth of 2.3% offset by a negative currency impact of 3.5%.

In 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately 20.5%, 15.6% and 12.3% of the total gross revenues.

In 2023, the Company had three wholesalers distributing products for both segments that represented approximately 18.2%, 15.1% and 14.2% of the total gross revenues.

2024 Sales by geographic region (in billions)

5 unchanged sentences

sales were $34.0 billion, an increase of 9.0%.

International sales were $23.6 billion, a decrease of 1.5%, which included an operational decline of 0.2% and a negative currency impact of 1.3%.

International sales were $23.0 billion, a decrease of 2.5%, which included operational growth of 1.3% offset by a negative currency impact of 3.8%.

In 2024, acquisitions and divestitures had a net negative impact of 0.1% on the operational sales growth of the worldwide Innovative Medicine segment.

In fiscal 2024, the net impact of the Covid-19 Vaccine on the total Innovative Medicine and International change in operational sales was a negative 1.8% and 4.2%, respectively.

Major Innovative Medicine therapeutic area sales:

18 unchanged sentences

Other Neuroscience 1,175 1,553 (24.3) (20.7) (3.6)

1,553 1,734 (10.4) (5.9) (4.5)

Total Oncology 20,781 17,661 17.7 19.8 (2.1)

3 unchanged sentences

IMBRUVICA 3,038 3,264 (6.9) (5.2) (1.7)

TECVAYLI 549 395 38.8 39.8 (1.0)

ZYTIGA /abiraterone acetate 631 887 (28.8) (25.0) (3.8)

6 unchanged sentences

XARELTO 2,373 2,365 0.3 0.3 —

1,306 1,414 (7.6) (7.4) (0.2)

Other 1,189 1,306 (8.9) (7.8) (1.1)

Total Innovative Medicine Sales $56,964 54,759 4.0 % 5.7 % (1.7) %

* Percentage greater than 100% or not meaningful

(1) Previously referred to as Pharmaceutical

(2) Inclusive of RISPERDAL CONSTA which was previously disclosed separately

(3) Inclusive of INVOKANA which was previously disclosed separately

2024 Annual Report

Immunology products achieved sales of $18.1 billion in 2023, representing an increase of 6.6% as compared to the prior year.

Increased sales of STELARA (ustekinumab) were primarily driven by patient mix, market growth, and continued strength in Inflammatory Bowel Disease.

Growth of TREMFYA (guselkumab) was due to market growth, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis) and patient mix.

Additionally, SIMPONI/SIMPONI ARIA growth was driven by growth outside the U.S.

Lower sales of REMICADE (infliximab) were due to biosimilar competition.

Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market.

Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.

Immunology products sales were $17.8 billion in 2024, representing a decrease of 1.2% as compared to the prior year.

The decline of STELARA (ustekinumab) sales was driven by share loss primarily due to European biosimilar entrants.

Lower sales of REMICADE (infliximab) was due to continued biosimilar competition.

The growth of TREMFYA (guselkumab) was due to market growth and share gains.

Sales of STELARA in the United States were approximately $6.7 billion in fiscal 2024.

1 unchanged sentence

The Company has settled certain litigation under the Biosimilar Price Competition and Innovation Act of 2009.

As a result of these settlements and other agreements with separate third parties, the Company does not anticipate the launch of a biosimilar version of STELARA until January 1, 2025 in the United States.

Infectious disease products sales were $4.4 billion in 2023, a decline of 18.9% as compared to the prior year primarily driven by a decline in COVID-19 vaccine revenue and loss of exclusivity of PREZISTA .

Neuroscience products sales were $7.1 billion in 2023, representing an increase of 3.6% as compared to the prior year.

The growth of SPRAVATO (esketamine) was driven by ongoing launches as well as increased physician confidence and patient demand.

Growth was partially offset by declines in RISPERDAL/RISPERDAL CONSTA and the paliperidone long-acting injectables outside the U.S.

due to the XEPLION loss of exclusivity in the European Union.

According to patent settlement and license agreements, the Company expects continued launches of biosimilar versions of STELARA in Europe and the United States in 2025 which will impact the Company’s sales of STELARA.

Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market.

Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.

Infectious disease products sales were $3.4 billion in 2024, a decline of 23.1% as compared to the prior year primarily driven by a decline in COVID-19 vaccine revenue.

Neuroscience products sales were $7.1 billion in 2024, representing a decrease of 0.4% as compared to the prior year primarily driven by a decline in Other Neuroscience.

The decline was partially offset by the growth of SPRAVATO (esketamine) driven by the ongoing launch and increased physician and patient demand.

Oncology products achieved sales of $20.8 billion in 2024, representing an increase of 17.7% as compared to the prior year.

Sales of DARZALEX (daratumumab) were driven by continued share gains in all regions and market growth.

Growth of ERLEADA (apalutamide) was due to continued share gains and market growth in Metastatic Castration Resistant Prostate Cancer.

Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by the ongoing launch, share gains and capacity improvement.

Additionally, sales from the launch of TECVAYLI (teclistamab-cqyv) and TALVEY (talquetamab-tgvs), included in Other Oncology, contributed to the growth.

Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth.

Growth of ERLEADA (apalutamide) was primarily due to continued share gains and market growth.

Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains, capacity expansion and manufacturing efficiencies.

Additionally, sales from the ongoing launches of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab), included in Other Oncology, contributed to the growth.

Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.

Pulmonary Hypertension products sales were $4.3 billion, representing an increase of 12.3% as compared to the prior year.

Sales growth was due to favorable patient mix, share gains and market growth from UPTRAVI (selexipag) and OPSUMIT (macitentan) partially offset by declines in Other Pulmonary Hypertension.

Cardiovascular/Metabolism/Other products sales were $3.7 billion, a decline of 5.5% as compared to the prior year.

The decline of XARELTO (rivaroxaban) sales was primarily driven by unfavorable patient mix and access changes.

Sales growth of both OPSUMIT (macitentan) and UPTRAVI (selexipag) was driven by market growth and share gains.

Growth in Other Pulmonary Hypertension was driven by OPSYNVI (macitentan/tadalafil).

Cardiovascular/Metabolism/Other products sales were $3.6 billion, a decline of 3.0% as compared to the prior year driven by declines in Other.

The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location.

4 unchanged sentences

federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities.

This policy had discount implications which positively impacted sales to customers in 2023.

During 2024, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs as follows:

(Chemical Name) Indication US

AKEEGA (Niraparib and Abiraterone Acetate) First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer (MAGNITUDE) • •

BALVERSA (erdafitinib) Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations (THOR) • •

CARVYKTI (ciltacabtagene autoleucel) Treatment for Relapsed and Refactor multiple myeloma with 1-3 PL (CARTITUDE-4) • •

DARZALEX (daratumumab) Treatment for frontline multiple myeloma transplant eligible (PERSEUS) • •

DARZALEX (daratumumab) Treatment for frontline multiple myeloma transplant ineligible (CEPHEUS) • •

DARZALEX (daratumumab) Treatment as subcutaneous monotherapy for high-risk smoldering multiple myeloma (AQUILA) • •

EDURANT (rilpivirine) Treatment for pediatric patients (2-12 years old) with HIV • •

(apalutamide) Tablet reduction • •

OPSUMIT (macitentan) Treatment for pediatric pulmonary arterial hypertension •

OPSYNVI (mecitentan/tadalafil STCT) Treatment for pulmonary arterial hypertension • •

IMBRUVICA (ibrutinib) Treatment for frontline MCL (Triangle) •

nipocalimab Treatment for Generalized Myasthenia Gravis • •

OPSUMIT (macitentan) Treatment for pediatric pulmonary arterial hypertension (TOMORROW) • •

OPSYNVI (macitentan/tadalafil STCT) Treatment for pulmonary arterial hypertension • •

REKAMBYS Treatment for Adolescents HIV •

RYBREVANT (amivantamab) In Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations (PAPILLON) • •

RYBREVANT / lazertinib Treatment for Non-Small Cell Lung Cancer 2L (MARIPOSA) • •

RYBREVANT / lazertinib Treatment for Non-Small Cell Lung Cancer 2L (MARIPOSA-2) • •

TECVAYLI (teclistamab) Treatment of Patients with Relapsed Refractory Multiple Myeloma Biweekly Dosing •

TALVEY (talquetamab) Treatment of Patients with Relapsed and Refractory Multiple Myeloma • •

RYBREVANT (amivantamab) Treatment for subcutaneous (PALOMA-3) • •

RYBREVANT / LAZCLUZE Treatment for Non-Small Cell Lung Cancer (MARIPOSA) • •

RYBREVANT Treatment for Non-Small Cell Lung Cancer 2L (MARIPOSA-2) • •

SIMPONI (golimumab) Treatment of Patients with Pediatric Ulcerative Colitis • •

SPRAVATO (esketamine) monotherapy Treatment of Patients with Treatment Resistant Depression (TRD4005) •

STELARA (ustekinumab) Treatment of Patients with Pediatric Crohn's Disease •

TREMFYA (guselkumab) Treatment of Patients with Ulcerative Colitis (QUASAR) • •

TREMFYA (guselkumab) Subcutaneous Induction for treatment of patients with Ulcerative Colitis (ASTRO) •

TREMFYA (guselkumab) Subcutaneous Induction for treatment of patients with Crohn's Disease (GRAVITI) • •

TREMFYA (guselkumab) Treatment of Patients with Crohn's Disease (GALAXI) • •

TREMFYA (guselkumab) Treatment of Patients with Pediatric Psoriasis •

UPTRAVI (selexipag) Treatment of Patients with Pediatric Pulmonary Arterial Hypertension (SALTO) •

2024 Annual Report

3 unchanged sentences

International sales were $15.5 billion, an increase of 2.6% as compared to the prior year, which included operational growth of 5.4% and a negative currency impact of 2.8%.

In 2023, the net impact of acquisitions and divestitures on the MedTech segment worldwide operational sales growth was a positive 4.6% primarily related to the Abiomed acquisition.

In 2024, the net impact of acquisitions and divestitures on the MedTech segment worldwide operational sales growth was a positive 1.5% primarily related to the Shockwave acquisition.

Major MedTech franchise sales:

10 unchanged sentences

Spine, Sports & Other 2,926 2,947 (0.7) (0.1) (0.6)

Interventional Solutions 6,350 4,300 47.7 49.8 (2.1)

Cardiovascular (1)

7,707 6,350 21.4 22.8 (1.4)

Electrophysiology 5,267 4,688 12.3 14.0 (1.7)

Abiomed 1,496 1,306 14.5 14.9 (0.4)

Other Interventional Solutions 356 332 7.1 9.9 (2.8)

Shockwave (2)

Other Cardiovascular 380 356 6.9 8.4 (1.5)

Vision 5,146 5,072 1.5 3.0 (1.5)

2 unchanged sentences

Total MedTech Sales $31,857 30,400 4.8 % 6.2 % (1.4) %

(1) Previously referred to as Interventional Solutions

(2) Acquired on May 31, 2024

* Percentage greater than 100% or not meaningful

The Surgery franchise sales were $10.0 billion in 2023, representing an increase of 3.6% from 2022.

The growth in Advanced Surgery was primarily driven by Biosurgery global procedure growth and strength of the portfolio as well as uptake of new products in Endocutters and Energy.

The growth was partially offset by competitive pressures and volume-based procurement impacts in Endocutters and Energy.

The growth in General Surgery was primarily driven by increased procedures coupled with technology penetration and benefits from the differentiated Wound Closure portfolio.

The Surgery franchise sales were $9.8 billion in 2024, representing a decrease of 1.9% from 2023.

The decline in Advanced Surgery was primarily due to China volume-based procurement across all platforms and competitive pressures in Energy and Endocutters.

This was partially offset by the strength of the portfolio and commercial execution in Biosurgery as well as the strength of new products in Endocutters.

Growth in General Surgery was primarily driven by technology penetration and benefits from the differentiated Wound Closure portfolio as well as increased procedure volume.

This growth was offset by the negative impact of currency and the Acclarent divestiture.

The Orthopaedics franchise sales were $9.2 billion in 2024, representing an increase of 2.4% from 2023.

The growth in hips reflects global procedure growth and continued strength of the portfolio partially offset by volume-based procurement impacts and Russia sanctions.

The growth in knees was primarily driven by procedures, benefits from recent product additions to the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution.

This was partially offset by stocking dynamics, primarily outside the U.S.

The growth in Trauma was driven by global procedures and the adoption of recently launched products.

This was partially offset by volume-based procurement impacts.

The growth in Spine, Sports & Other was primarily driven by Digital Solutions, Shoulders, Sports and Craniomaxillofacial products partially offset by Russia sanctions and supply constraints, primarily outside the U.S.

The Interventional Solutions franchise achieved sales of $6.4 billion in 2023, representing an increase of 47.7% from 2022, which includes sales from Abiomed acquired on December 22, 2022.

Electrophysiology grew by double digits due to global procedure growth, new product performance and commercial execution.

This was partially offset by the impacts of volume-based procurement in China.

Abiomed sales reflect the strength of all commercialized regions and continued adoption of Impella 5.5 and Impella RP.

The fiscal 2024 includes a one-time revenue recognition timing change related to certain products across all Orthopaedic platforms in the U.S.

which positively impacted the worldwide Orthopaedics franchise growth as well as the negative impact from the near-term revenue disruption related to the previously announced Orthopaedics restructuring.

The growth in Hips reflects continued strength of the portfolio primarily in the Anterior approach, and global procedure growth.

The growth in Knees was primarily driven by the ATTUNE portfolio, pull through related to the VELYS Robotic assisted solution and global procedure growth.

Growth in Trauma was driven by the adoption of recently launched products.

The decline in Spine, Sports & Other was primarily driven by competitive pressures and impacts from China volume-based procurement.

This was partially offset by growth in the U.S.

The Cardiovascular franchise, which includes sales from Shockwave Medical (Shockwave) acquired on May 31, 2024, achieved sales of $7.7 billion in 2024, representing an increase of 21.4% from 2023.

Electrophysiology growth was driven by global procedure growth, new product performance and commercial execution.

This was partially offset by the impacts of volume-based procurement in China and competitive pressures in Pulsed Field Ablation catheters in the U.S.

Abiomed sales reflect the strength of all major commercialized regions driven by the continued adoption of Impella 5.5 and Impella RP.

The Vision franchise achieved sales of $5.1 billion in 2024, representing an increase of 1.5% from 2023.

The Contact Lenses/Other growth was primarily driven by the continued strong performance in the ACUVUE OASYS 1-Day family including recent launches and commercial execution.

This was partially offset by impacts of U.S.

stocking dynamics, Russia sanctions, impacts from strategic portfolio decisions and supply challenges.

The Surgical operational growth was primarily driven by cataract procedure growth, continued strength of recent innovations and reduction of prior year stocking outside the U.S.

This was partially offset by softer Refractive and premium IOL markets and Russia sanctions.

Contact Lenses/Other growth was primarily driven by price actions, continued strong performance in the ACUVUE OASYS 1-Day family of products (including recent launches), impacts from a one-time change in contract shipping terms in the U.S.

and lapping of prior year impacts of Russian sanctions partially offset by U.S.

distributor stocking dynamics.

Surgical growth was primarily driven by the continued strength of recent innovations and commercial execution partially offset by China volume-based procurement and competitive pressures in the U.S.

Analysis of consolidated earnings before provision for taxes on income

9 unchanged sentences

Percentages in chart are as a percent to total sales)

2024 Annual Report

Cost of products sold:

Cost of products sold increased as a percent to sales driven by:

• Commodity inflation, unfavorable product mix, restructuring related excess inventory costs and Abiomed amortization in the MedTech business

Cost of products sold decreased as a percent to sales driven by:

• Lower one-time COVID-19 vaccine supply network related exit costs in 2024 ($0 in 2024 versus $0.2 billion 2023) in the Innovative Medicine business

• Prior year restructuring related excess inventory costs in the MedTech business

partially offset by

• Favorable patient mix and lower one-time COVID-19 vaccine manufacturing related exit costs in 2023 in the Innovative Medicine business

The intangible asset amortization expense included in cost of products sold was $4.5 billion and $3.9 billion for the fiscal years 2023 and 2022, respectively.

2023 Annual Report

• The fair value Inventory step-up of $0.4 billion related to the business combination accounting associated with Shockwave

The intangible asset amortization expense included in cost of products sold was $4.5 billion for both fiscal years 2024 and 2023.

Selling, Marketing and Administrative expense:

Selling, Marketing and Administrative Expenses decreased slightly as a percent to sales driven by:

• Leveraging in Selling and Marketing expenses both the Innovative Medicine and MedTech businesses

Selling, Marketing and Administrative Expenses increased as a percent to sales driven by:

• Increased commercial investment in the Innovative Medicine business

partially offset by

• An increase in administrative costs

• Optimization efforts related to the residual costs associated with the Kenvue separation

Research and Development expense:

9 unchanged sentences

The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products.

Research and Development was flat as a percent to sales primarily driven by:

• Higher milestone payments in the Innovative Medicine business

• Acquired in-process research & development asset from the Laminar acquisition in the MedTech business in the fiscal year 2023

• Portfolio prioritization in the Innovative Medicine business

Research and Development increased as a percent to sales primarily driven by:

• Acquired in-process research & development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition) and pipeline advancement in the Innovative Medicine business

• Acquired in-process research & development expense of $0.5 billion from the V-Wave acquisition in the MedTech business

In-Process Research and Development Impairments (IPR&D):

In the fiscal year 2023, the Company recorded a charge of approximately $0.3 billion which included $0.2 billion related to market dynamics associated with a non-strategic asset (M710) acquired as part of the acquisition of Momenta Pharmaceuticals in 2020, In the fiscal year 2022, the Company recorded an intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).

Additional information regarding efficacy of the AD indication and HS indication became available which led the Company to the decision to terminate the development of bermekimab for both AD and HS.

The Company acquired all rights to bermekimab from XBiotech, Inc.

in the fiscal year 2020.

In the fiscal year 2024, the Company recorded a charge of approximately $0.2 billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.

There was also a partial impairment of this asset for $0.2 billion in the fiscal 2023.

This asset is now fully impaired.

Other (Income) Expense, Net:

1 unchanged sentence

(JJDC), changes in the fair value of securities, investment (income)/loss related to employee benefit programs, gains and losses on divestitures, certain transactional currency gains and losses, acquisition and divestiture related costs, litigation accruals and settlements, as well as royalty income.

Other (income) expense, net for the fiscal year 2023 was unfavorable by $5.8 billion as compared to the prior year primarily due to the following:

Other (income) expense, net for the fiscal year 2024 reflected less expense of $1.9 billion as compared to the prior year primarily due to the following:

(Dollars in Billions)(Income)/Expense 2024 2023 Change

Litigation related (1)

$5.5 6.9 (1.4)

Acquisition, Integration and Divestiture related (2)

Changes in the fair value of securities (3)

1 unchanged sentence

COVID-19 vaccine manufacturing exit related costs 0.1 0.4 (0.3)

Acquisition, Integration and Divestiture related (3)

Monetization of royalty rights (0.3) 0.0 (0.3)

Employee benefit plan related (0.9) (1.4) 0.5

1 unchanged sentence

Total Other (Income) Expense, Net $4.7 6.6 (1.9)

(1) 2023 was primarily related to the approximately $7.0 billion charge for talc (See Note 19 to the Consolidated Financial Statements for more details) and favorable intellectual property related litigation settlements of approximately $0.3 billion.

2022 was primarily related to pelvic mesh.

(2) The fiscal 2023 includes $0.4 billion related to the unfavorable change in the fair value of the remaining stake in Kenvue and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.

(3) 2023 primarily related to the impairment of Ponvory and one-time integration costs related to the acquisition of Abiomed.

2022 was primarily costs related to the acquisition of Abiomed.

(1) The fiscal years 2024 and 2023 include charges primarily for talc matters (See Note 19 to the Consolidated Financial Statements for more details).

The fiscal year 2023 includes favorable intellectual property related litigation settlements of approximately $0.3 billion.

(2) The fiscal year 2024 is primarily related to the acquisition of Shockwave.

The fiscal year 2023 is primarily related to the impairment of Ponvory and one-time integration costs related to the acquisition of Abiomed.

(3) The fiscal year 2024 includes the loss of $0.4 billion on the completion of the debt for equity exchange of the retained stake in Kenvue.

The fiscal year 2023 includes $0.4 billion related to the unfavorable change in the fair value of the remaining stake in Kenvue and $0.4 billion related to the partial impairment of Idorsia convertible debt and the change in the fair value of the Idorsia equity securities held.

Interest (Income) Expense:

Interest income in the fiscal year 2023 was $1.3 billion as compared to interest income of $0.5 billion in the fiscal year 2022 primarily due to higher rates of interest earned on cash balances.

Interest expense in the fiscal year 2023 was $0.8 billion as compared to interest expense of $0.3 billion in the fiscal year 2022 primarily due to higher interest rates on debt balances.

Interest income in the fiscal years 2024 and 2023 was $1.3 billion.

Interest expense in the fiscal years 2024 and 2023 was $0.8 billion.

Cash, cash equivalents and marketable securities totaled $24.5 billion at the end of 2024, and averaged $23.7 billion as compared to the cash, cash equivalents and marketable securities total of $22.9 billion and $22.6 billion average balance in 2023.

The total debt balance at the end of 2024 was $36.6 billion with an average debt balance of $33.0 billion as compared to $29.3 billion at the end of 2023 and an average debt balance of $34.5 billion.

The lower average cash, cash equivalents and marketable securities was primarily due to the acquisition of Abiomed in late December of 2022.

The lower average debt balance was primarily due to the repayment of commercial paper.

The higher debt balance was due to the senior unsecured notes issued by the Company in the fiscal second quarter of 2024.

The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024 and for general corporate purposes.

Income before tax by segment

Income (loss) before tax by segment of business were as follows:

Income Before Tax Segment Sales Percent of Segment Sales

Income Before Tax Segment Sales Percent of Segment

(Dollars in Millions) 2024 2023 2024 2023 2024 2023

7 unchanged sentences

(2) Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.

Fiscal 2023 includes an approximately $7.0 billion charge related to talc matters and the approximately $0.4 billion unfavorable change in the fair value of the retained stake in Kenvue.

The fiscal years 2024 and 2023 include charges for talc matters of approximately $5.1 billion and $7.0 billion, respectively.

The fiscal 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.

The fiscal year 2023 includes an approximately $0.4 billion unfavorable change in the fair value of the retained stake in Kenvue.

2024 Annual Report

1 unchanged sentence

In 2024, the Innovative Medicine segment income before tax as a percent to sales was 33.2% versus 33.3% in 2023.

The increase in the income before tax as a percent of sales was primarily driven by the following:

• Lower one-time COVID-19 Vaccine related exit costs of $0.7 billion in 2023 versus $1.5 billion in 2022

• Lower In-process research & development impairments of $0.2 billion in 2023 versus $0.8 billion in 2022

• Unfavorable changes in the fair value of securities in 2023 of $0.4 billion as compared to $0.7 billion in 2022

• Lower litigation related expense of $0.2 billion

• Leveraging in selling and marketing expenses

• R&D Portfolio prioritization

The decrease in the income before tax as a percent of sales was primarily driven by the following:

• Acquired in-process research and development expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody

• Litigation expense of $0.4 billion in 2024, primarily related to Risperdal Gynecomastia, versus favorable litigation related items of $0.1 billion in 2023

• Increased research and development to advance the pipeline

• Increased commercial investment in selling and marketing expenses

partially offset by

• Monetization of royalty rights of $0.3 billion in 2024

• Lower one-time COVID-19 Vaccine related exit costs of $0.1 billion in 2024 versus $0.7 billion in 2023

• Lower amortization expense of $0.2 billion in 2024 versus 2023

• Restructuring charges of $0.1 billion in 2024 versus $0.5 billion in 2023

• Impairment of Ponvory in 2023

• Higher milestone payments in 2023

• A gain of $0.1 billion in 2024 as compared to a loss of $0.4 billion in 2023 related to changes in the fair value of securities

MedTech segment:

1 unchanged sentence

The decrease in the income before tax as a percent to sales was primarily driven by the following:

• Higher amortization expense of $0.5 billion in 2023 related to Abiomed

• Expense of $0.4 billion for an acquired in process research and development asset from the Laminar acquisition in 2023

• Commodity inflation in 2023

• Acquisition and integration related costs of $1.0 billion in 2024 (primarily related to the Shockwave acquisition) versus $0.2 billion in 2023 related to Abiomed

• Acquired in-process research and development expense of $0.5 billion from the V-Wave acquisition in 2024

• Higher amortization expense of $0.2 billion in 2024 related to Shockwave

partially offset by

• Income from litigation settlements of $0.1 billion in 2023 versus expense of $0.6 billion in 2022

• Lower integration/acquisition costs related to Abiomed of $0.2 billion in 2023 versus $0.3 billion in 2022

• Leveraging in selling and marketing expenses in 2023

• A gain of $0.2 billion related to the Acclarent divestiture in 2024

• Restructuring related charge of $0.2 billion in 2024 versus $0.3 billion in 2023

Restructuring:

2 unchanged sentences

The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development.

The pre-tax restructuring charge of approximately $0.5 billion in the fiscal year 2023, of which $449 million was recorded in Restructuring and $30 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, included the termination of partnered and non-partnered program costs and asset impairments.

The pre-tax restructuring charge of approximately $0.1 billion in the fiscal year 2024 was recorded in Restructuring on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered development program costs, asset impairments and asset divestments.

The pre-tax restructuring charge of approximately $0.5 billion in the fiscal year 2023, of which $449 million was recorded in Restructuring and $30 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, and included the termination of partnered and non-partnered program costs and asset impairments.

Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced.

The program was completed in the fiscal fourth quarter of 2024.

In the fiscal year 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements.

The pre-tax restructuring expense of $0.2 billion in the fiscal year 2024, of which $132 million was recorded in Restructuring and $35 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included costs related to market and product exits.

The pre-tax restructuring expense of $0.3 billion in the fiscal year 2023, of which $40 million was recorded in Restructuring and $279 million was recorded in Cost of products sold on the Consolidated Statement of Earnings, primarily included inventory and instrument charges related to market and product exits.

In 2022, the Company recorded a pre-tax charge of $0.4 billion related to a restructuring program of its Global Supply Chain.

The Global Supply Chain program was announced in the second quarter of 2018 and was completed in the fiscal fourth quarter of 2022.

Total project costs of approximately $0.5 billion have been recorded since the restructuring was announced.

See Note 20 to the Consolidated Financial Statements for additional details related to the restructuring programs.

1 unchanged sentence

The worldwide effective income tax rate from continuing operations was 15.7% in 2024 and 11.5% in 2023.

For discussion related to the fiscal year 2024 provision for taxes refer to Note 8 to the Consolidated Financial Statements.

On December 15, 2022, the European Union (EU) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide.

As of December 31, 2023, several EU and non-EU countries have enacted Pillar 2 legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later.

The Company is estimating that as result of this legislation the 2024 effective tax rate will increase by approximately 1.5% or 150 basis points compared to fiscal 2023.

Further legislation, guidance and regulations that may be issued in fiscal 2024, as well as other business events, may impact this estimate.

For discussion related to the fiscal 2023 provision for taxes refer to Note 8 to the Consolidated Financial Statements.

Several EU and non-EU countries have enacted Pillar Two legislation with an initial effective date of January 1, 2024, with other aspects of the law effective in 2025 or later.

In the fiscal year 2024, the net impact of Pillar Two legislation was less than 1.0% to the Company’s effective tax rate.

While countries continue to enact new provisions or issue new regulations, based on current guidance, the Company expects the net impact of Pillar Two in fiscal year 2025 to be up to 1.0% to the Company’s effective tax rate.

Liquidity and capital resources

5 unchanged sentences

24.3 cash generated from operating activities

0.9 net cash from investing activities

(18.6) net cash used by investing activities

(3.1) net cash used by financing activities

6 unchanged sentences

$14.1 Net Earnings

(14.9) gain on the Kenvue separation, net gain on sale of assets/businesses and the deferred tax provision partially offset by non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and charge for purchase of in process research and development assets

5.6 an increase in current and non-current liabilities

(3.5) an increase in other current and non-current assets

8.4 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and charges for acquired in-process research and development assets partially offset by net gain on sale of assets/businesses and the deferred tax provision

1.7 a decrease in other current and non-current assets

1.6 an increase in accounts payable and accrued liabilities

2 unchanged sentences

2024 Annual Report

Cash flow from investing activities of $0.9 billion was primarily due to:

Cash flow used for investing activities of $18.6 billion was primarily due to:

(Dollars in billions)

$(4.4) additions to property, plant and equipment

(15.1) acquisitions, net of cash acquired

0.7 proceeds from the disposal of assets/businesses, net

(0.5) purchases of in-process research and development assets

(1.8) acquired in-process research and development assets

0.7 net sales of investments

1.5 credit support agreements activity, net

$0.9 Net cash from investing activities

(0.2) other (including capitalized licenses and milestones)

$(18.6) Net cash used for investing activities

Cash flow used for financing activities of $3.1 billion was primarily due to:

2 unchanged sentences

(2.4) repurchase of common stock

(10.8) net repayment from short and long term debt

11.0 net proceeds from short and long-term debt

0.8 proceeds from stock options exercised/employee withholding tax on stock awards, net

0.3 credit support agreements activity, net

8.0 Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation

4.2 proceeds from Kenvue initial public offering

(1.1) Cash transferred to Kenvue at separation

(0.1) other and rounding

(1.0) settlement of convertible debt acquired from Shockwave

$(3.1) Net cash used for financing activities

The following table summarizes cash taxes paid net of refunds:

(Dollars in Millions) 2024 2023 2022

$3,815 4,722 2,158

State and Local taxes 341 236 216

$4,156 4,958 2,374

Total Foreign 2,558 3,616 2,849

Total cash taxes paid net of refunds $6,714 $8,574 $5,223

(1) Includes TCJA foreign undistributed earnings payments of $2.0 billion in fiscal year 2024, $1.5 billion in fiscal year 2023 and $0.8 billion in fiscal year 2022

As of December 29, 2024, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities.

1 unchanged sentence

The debt balance at the end of 2024 was $36.6 billion as compared to $29.3 billion in 2023.

In the fiscal second quarter of 2024, the Company issued senior unsecured notes for a total of $6.7 billion.

For additional details on borrowings, see Note 7 to the Consolidated Financial Statements.

The net proceeds from this offering were used to fund the Shockwave acquisition which closed on May 31, 2024, and for general corporate purposes.

Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk.

The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.1 billion and the establishment of the approximately $9 billion reserve for talc matters (See Note 19 to the Consolidated Financial Statements for additional details).

The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's remaining balance to be paid on the agreement to settle opioid litigation for approximately $1.5 billion and the approximately $11.6 billion ($13.5 billion nominal) reserve for talc matters (See Note 19 to the Consolidated Financial Statements for additional details).

In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable.

On May 8, 2023, Kenvue, completed an initial public offering (the IPO) resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the Kenvue Common Stock), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion.

The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson divested interest was $2.5 billion and was recorded to additional paid-in capital.

The excess of the net proceeds from the IPO over the net book value of the Johnson & Johnson

divested interest was $2.5 billion and was recorded to additional paid-in capital.

As of the closing of the IPO, Johnson & Johnson owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock and at July 2, 2023, the non-controlling interest of $1.3 billion associated with Kenvue was reflected in equity attributable to non-controlling interests in the consolidated balance sheet.

1 unchanged sentence

The $31.4 billion of Johnson & Johnson common stock received in the exchange offer is recorded in Treasury stock.

Following the exchange offer, the Company owns 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023 and $3.9 billion as of December 31, 2023.

Following the exchange offer, the Company owned 9.5% of the total outstanding shares of Kenvue Common Stock that was recorded in other assets within continuing operations at the fair market value of $4.3 billion as of August 23, 2023 and $3.9 billion as of December 31, 2023.

Johnson & Johnson divested net assets of $11.6 billion as of August 23, 2023, and the accumulated other comprehensive loss attributable to the Consumer Health business at that date was $4.3 billion.

Additionally, at the date of the exchange offer,

Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue.

Additionally, at the date of the exchange offer, Johnson & Johnson decreased the non-controlling interest by $1.2 billion to record the deconsolidation of Kenvue.

This resulted in a gain on the exchange offer of $21.0 billion that was recorded in Net earnings from discontinued operations, net of taxes in the consolidated statements of earnings for the fiscal third quarter of 2023.

2 unchanged sentences

federal income tax purposes.

On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company’s Common Stock.

In the fiscal year 2022, approximately $2.5 billion was repurchased under the program.

In the fiscal year 2023, $2.5 billion has been repurchased and the repurchase program was completed.

On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper and received $3.6 billion of net cash proceeds to be used for general corporate purposes.

On May 17, 2024, the Company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper.

Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock.

This exchange resulted in a loss of approximately $0.4 billion recorded in Other (income) expense.

The following table summarizes the Company’s material contractual obligations and their aggregate maturities as of December 29, 2024:

To satisfy these obligations, the Company intends to use cash from operations.

(Dollars in Millions) Tax Legislation (TCJA) Debt Obligations Interest on

(Dollars in Millions) Tax Legislation

(TCJA) Debt Obligations Interest on

Debt Obligations Total

7 unchanged sentences

For tax matters, see Note 8 to the Consolidated Financial Statements.

For the proposed talc settlement payments, see Note 19 to the Consolidated Financial Statements.

2024 Annual Report

20 unchanged sentences

The fair market value of fixed rate securities may be adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than predicted if interest rates fall.

A 1% (100 basis points) change in spread on the Company’s interest rate sensitive investments would either increase or decrease the unrealized value of cash equivalents and current marketable securities by less than $0.8 billion.

The Company has access to substantial sources of funds at numerous banks worldwide.

In September 2023, the Company secured a new 364-day Credit Facility of $10 billion, which expires on September 5, 2024.

The Company early terminated the additional 364-day revolving Credit Facility of $10 billion, which had an expiration of November 21, 2023.

In June 2024, the Company secured a new 364-day Credit Facility of $10 billion, which expires on June 25, 2025.

Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins.

1 unchanged sentence

Total borrowings at the end of 2024 and 2023 were $36.6 billion and $29.3 billion, respectively.

The decrease in the debt balance was due to the repayment of commercial paper.

The increase in the borrowings was due to the issuance of new debt in 2024.

In 2024, net debt (cash and current marketable securities, net of debt) was $12.1 billion compared to net debt of $6.4 billion in 2023.

2 unchanged sentences

A summary of borrowings can be found in Note 7 to the Consolidated Financial Statements.

The Company increased its dividend in 2023 for the 61st consecutive year.

The Company increased its dividend in 2024 for the 62 nd consecutive year.

Cash dividends paid were $4.91 per share in 2024 and $4.70 per share in 2023.

13 unchanged sentences

Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing.

Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served.

Rebates and discounts are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served.

The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.

Sales returns are estimated and recorded based on historical sales and returns information.

Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.

Products that have lost patent exclusivity, or that otherwise exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.

Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall.

The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales.

In accordance with the Company’s accounting policies, the Company generally issues credit to customers for returned goods.

2 unchanged sentences

Sales returns reserves are recorded at full sales value.

Sales returns in the Innovative Medicine segments are almost exclusively not resalable.

Sales returns in the Innovative Medicine segment are almost exclusively not resalable.

Sales returns for certain franchises in the MedTech segment are typically resalable but are not material.

The Company infrequently exchanges products from inventory for returned products.

The sales returns reserve for the total Company has been less than 1.0% of annual net trade sales during the fiscal years 2023, 2022 and 2021.

The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal years 2024, 2023 and 2022.

Promotional programs, such as product listing allowances are recorded in the same period as related sales and include volume-based sales incentive programs.

2 unchanged sentences

The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers.

Profit-share payments were less than 2.0% of the total revenues in fiscal year 2023 and less than 3.0% of the total revenues in fiscal year 2022 and 2021 are included in sales to customers.

Profit-share payments were less than 2.0% of the total revenues in fiscal year 2024 and 2023, respectively, and less than 3.0% of the total revenues in the fiscal year 2022 and are included in sales to customers.

In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities.

5 unchanged sentences

2024 Annual Report

Below are tables that show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended December 31, 2023 and January 1, 2023.

Innovative Medicine segment

17 unchanged sentences

Total $13,093 49,253 (46,901) 15,445

(1) Includes reserve for customer rebates of $165 million at December 31, 2023 and $203 million at January 1, 2023, recorded as a contra asset.

(1) Includes reserve for customer rebates of $187 million at December 29, 2024 and $165 million at December 31, 2023, recorded as a contra asset.

(2) Includes prior period adjustments

19 unchanged sentences

Total $1,781 6,999 (7,037) 1,743

(1) Includes reserve for customer rebates of $740 million at December 31, 2023 and $802 million at January 1, 2023, recorded as a contra asset.

(1) Includes reserve for customer rebates of $704 million at December 29, 2024 and $740 million at December 31, 2023, recorded as a contra asset.

Income Taxes:

51 unchanged sentences

Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate.

The Company has accounted for operations in Argentina, Venezuela and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%.

The Company has accounted for operations in Argentina, Venezuela, Turkey and Egypt (beginning in the fiscal fourth quarter of 2024) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%.

This did not have a material impact to the Company's results in the period.

In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.

In December 2023, the Argentine government devalued the peso by approximately 50%.

During 2023, the Company recorded a charge of approximately $130 million related to operations in Argentina due to the application of highly inflationary accounting.

As of December 31, 2023, the Company’s Argentine subsidiaries represented less than 1.0% of the Company's consolidated assets, liabilities, revenues and profits from continuing operations;

therefore, the effect of a change in the exchange rate is not expected to have a material adverse effect on the Company's 2024 full-year results.

In July 2023, Janssen Pharmaceuticals, Inc.

(Janssen) filed litigation against the U.S.

Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program.

Department of Health and Human Services as well as the Centers for Medicare and Medicaid Services challenging the constitutionality of the IRA's Medicare Drug Price Negotiation Program.

The litigation requests a declaration that the IRA violates Janssen’s rights under the First Amendment and the Fifth Amendment to the Constitution and therefore that Janssen is not subject to the IRA’s mandatory pricing scheme.

The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as litigation filed by Janssen and other pharmaceutical companies remains ongoing and while CMS has publicly announced the maximum fair price for each of the selected drugs, implementation of the program is still in progress.

In April 2024, Janssen appealed the district court’s denial of its summary judgment motion to the Third Circuit.

Russia-Ukraine War

Although the long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material.

As of and for each of the fiscal years ending December 31, 2023 and January 1, 2023, the business of the Company’s Russian subsidiaries represented less than 1% of the Company’s consolidated assets and represented 1% of revenues.

As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company’s Russian subsidiaries represented less than 1% of the Company’s consolidated assets and revenues.

The Company does not maintain Ukraine subsidiaries subsequent to the Kenvue separation.

In early March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia.

In March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia.

The Company continues to supply products relied upon by patients for healthcare purposes.

Conflict in the Middle East

Although the long-term implications of Israel's conflict are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2023, including accounts receivable or inventory reserves, was not material.

As of and for the fiscal year ending December 31, 2023, the business of the Company’s Israel subsidiaries represented 1% of the Company’s consolidated assets and represented less than 1% of revenues.

Although the long-term implications of the conflict in the Middle East are difficult to predict at this time, the financial impact of the conflict in the fiscal year 2024, including accounts receivable or inventory reserves, was not material.

As of and for each of the fiscal years ending December 29, 2024 and December 31, 2023, the business of the Company’s Israel subsidiaries represented 1% of the Company’s consolidated assets and represented less than 1% of revenues.

The Company is exposed to fluctuations in currency exchange rates.

8 unchanged sentences

The Company faces various worldwide healthcare changes that may continue to result in pricing pressures that include healthcare cost containment and government legislation relating to sales, promotions, pricing and reimbursement of healthcare products.

Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage may continue to impact the Company’s businesses.

2024 Annual Report

The Company also operates in an environment increasingly hostile to intellectual property rights.

29 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 7. Management’s Discussion and Analysis